ViewRay has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for an updated version of its MRIdian MRI-guided radiation therapy system.
The new features of MRIdian A3i include new MRI sequences, on-table autocontouring tools, automated workflow, multiplanar tissue tracking, and automated beam gating.
Currently, 46 MRIdian systems are installed around the globe, according to ViewRay.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
